Oncology Information System Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type [Services (Consulting Services, Implementation Services, Post Sale and Maintenance) (Software (Treatment Planning, Patient Information)] By Application (Medical Oncology, Surgical Oncology, Radiation Oncology) By End-User (Hospitals, Oncology Clinics, Research Centres, Oncology Institutes) Region Forecast 2020-2031

Oncology Information System Market size was valued at US$ 7.1 billion in 2024 and is expected to reach US$ 12.2 billion by 2031, growing at a significant CAGR of 7.9% from 2025-2031. An oncology information system is used for the management of data belonging to oncology patient treatment schedules, plans of treatment, treatment delivery, summary, and results of the treatment. Oncology information systems encompassed the information exchange between the department of radiotherapy and the overall healthcare enterprise.

The Oncology Information System (OIS) is a piece of software that is used to manage and maintain patient profiles in healthcare settings such as clinics, hospitals, and research labs. Its goals include increasing efficiency, connecting diverse oncology specialties, and guaranteeing the most efficient use of resources to support the oncology center's efficient workflow.

This software provides a tool for keeping track of patient profiles who are having cancer treatment, hence improving patient efficiency and safety. It's employed in Medical Oncology, Surgical Oncology, and Radiation Oncology, among other fields. For medical safety purposes treatment and demographic information of patient data is to be shared among those systems. Oncology information systems are to be connected with other information systems. The market is highly competitive due to the presence of many market players in the global oncology information market. Companies are focused on various growth strategies such as agreements, collaborations, and new product launches in order to strengthen their market presence and improve their product portfolio.

Key Developments:

• In October 2024, GE HealthCare introduced CareIntellect for Oncology, a new cloud-based application that utilizes generative AI. This application consolidates multi-modal patient data from various systems into a single view. It employs generative AI to summarize clinical notes and reports. GE HealthCare designed CareIntellect for Oncology to highlight relevant data, enabling care teams to quickly assess disease progression and identify potential deviations from the treatment plan. This functionality helps clinicians determine appropriate next steps and inform proactive interventions.
• In September 2024, Varian and Ballad Health announced a new 10-year agreement, building on their existing relationship. This agreement focuses on improving clinical outcomes and driving value across the Ballad Health system, with the goal of providing world-class care regardless of patient location. Ballad Health's investment highlights its dedication to expanding patient and regional healthcare professional access to advanced technology. The agreement encompasses the purchase of hardware, software, digital solutions, and Advanced Oncology Solutions Professional and Clinical Services.
• In August 2024, Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced the expansion of its oncology offerings for NovaSeq™ X Series customers. The company recently began offering the newly verified high-throughput version of TruSight™ Oncology 500 (TSO 500 HT) and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). These assays allow labs to confidently broaden their oncology testing research using tissue and liquid biopsy samples. The NovaSeq X Series now offers these assays with improved sequencing economics, faster run times, and larger batch sizes.